These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 1687761)

  • 41. The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system.
    Kidd E; Bouchelet de Vendegies I; Levy JC; Hamon M; Gozlan H
    Eur J Pharmacol; 1992 Jan; 211(1):133-6. PubMed ID: 1618262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 5-HT3 receptor antagonists reverse helpless behaviour in rats.
    Martin P; Gozlan H; Puech AJ
    Eur J Pharmacol; 1992 Feb; 212(1):73-8. PubMed ID: 1532555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [3H]zacopride: ligand for the identification of 5-HT3 recognition sites.
    Barnes NM; Costall B; Naylor RJ
    J Pharm Pharmacol; 1988 Aug; 40(8):548-51. PubMed ID: 2907008
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zacopride and its optical isomers produce stereoselective antagonism of a 2-methylserotonin discriminative stimulus.
    Young R; Glennon RA
    Eur J Pharmacol; 1992 Feb; 212(1):117-9. PubMed ID: 1555633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emetic activity of zacopride in ferrets and its antagonism by pharmacological agents.
    Sancilio LF; Pinkus LM; Jackson CB; Munson HR
    Eur J Pharmacol; 1990 Jun; 181(3):303-6. PubMed ID: 2384137
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of the serotonin-4 receptor agonist zacopride on aldosterone secretion from the human adrenal cortex: in vivo and in vitro studies.
    Lefebvre H; Contesse V; Delarue C; Soubrane C; Legrand A; Kuhn JM; Wolf LM; Vaudry H
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1662-6. PubMed ID: 8263156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral buspirone causes a shift in the dose-response curve between the elevated-plus maze and Vogel conflict tests in Long-Evans rats: relation of brain levels of buspirone and 1-PP to anxiolytic action.
    Vaidya AH; Rosenthal DI; Lang W; Crooke JJ; Benjamin D; Ilyin SE; Reitz AB
    Methods Find Exp Clin Pharmacol; 2005 May; 27(4):245-55. PubMed ID: 16082425
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret.
    Middlefell VC; Price TL
    Br J Pharmacol; 1991 May; 103(1):1011-2. PubMed ID: 1831684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test.
    De Angelis L; Furlan C
    Pharmacol Biochem Behav; 2000 Apr; 65(4):649-53. PubMed ID: 10764917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The emetic activity of centrally administered cisplatin in cats and its antagonism by zacopride.
    Smith WL; Callaham EM; Alphin RS
    J Pharm Pharmacol; 1988 Feb; 40(2):142-3. PubMed ID: 2897451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors.
    Urigüen L; Pérez-Rial S; Ledent C; Palomo T; Manzanares J
    Neuropharmacology; 2004 Jun; 46(7):966-73. PubMed ID: 15081793
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of a new anxiolytic, DN-2327, on learning and memory in rats.
    Wada T; Fukuda N
    Pharmacol Biochem Behav; 1992 Mar; 41(3):573-9. PubMed ID: 1350101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The phenomenon of one-trial tolerance to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze test is abolished by previous administration of chlordiazepoxide or buspirone.
    Escarabajal MD; Torres C; Flaherty CF
    Life Sci; 2003 Jul; 73(8):1063-74. PubMed ID: 12818358
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single dose human pharmacology of umespirone.
    Holland RL; Wesnes K; Dietrich B
    Eur J Clin Pharmacol; 1994; 46(5):461-8. PubMed ID: 7957544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prevention and treatment of the gastric symptoms of radiation sickness.
    Dubois A; Fiala N; Boward CA; Bogo V
    Radiat Res; 1988 Sep; 115(3):595-604. PubMed ID: 3174940
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On the risk concerns of zacopride, a moderate IK1 channel agonist with cardiac protective action.
    Wu BW; Cao JM
    J Cardiovasc Pharmacol; 2014 Oct; 64(4):357-9. PubMed ID: 25072868
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dose related effects of buspirone on serum electrolyte balance, plasma osmolality and systolic blood pressure (SBP) in rats.
    Farooq R; Haleem DJ; Haleem MA
    Pak J Pharm Sci; 2007 Oct; 20(4):295-9. PubMed ID: 17604252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative autoradiographic mapping of 5-HT3 receptors in the rat CNS using [125I]iodo-zacopride and [3H]zacopride as radioligands.
    Laporte AM; Koscielniak T; Ponchant M; Vergé D; Hamon M; Gozlan H
    Synapse; 1992 Apr; 10(4):271-81. PubMed ID: 1585260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Action of serotonin in the medial prefrontal cortex: mediation by serotonin3-like receptors.
    Ashby CR; Edwards E; Wang RY
    Synapse; 1992 Jan; 10(1):7-15. PubMed ID: 1536032
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of stereoisomers of zacopride to analyze actions of 5-hydroxytryptamine on enteric neurons.
    Wade PR; Mawe GM; Branchek TA; Gershon MD
    Am J Physiol; 1991 Jan; 260(1 Pt 1):G80-90. PubMed ID: 1987811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.